Linked Life Data

16135465

Source:http://linkedlifedata.com/resource/pubmed/id/16135465

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
25
pubmed:dateCreated
2005-9-1
pubmed:abstractText
To determine the maximum-tolerated dose, pharmacodynamics, and safety of the combination of bortezomib and carboplatin in recurrent ovarian cancer.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0732-183X
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5943-9
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer.
pubmed:affiliation
Developmental Chemotherapy Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA. aghajanc@mskcc.org
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, U.S. Gov't, P.H.S., Clinical Trial, Phase I, Research Support, N.I.H., Extramural